The Biotech Stocks Tackling the World’s Most Common Cancer

By Patrick Davis

Mar 17, 2025

4 min read

Medicus Pharma (NASDAQ: MDCX) joins Roche, Regeneron, and Bristol-Myers in the 360i BCC market matrix. Discover its breakthrough innovation in skin cancer care.

Sponsored by: Medicus Pharma. Discover their stock story.

The growth of the basal cell carcinoma treatment market is strongly supported by increased investment in research. Companies are actively developing new medications designed to target the specific molecular pathways responsible for basal cell carcinoma, which helps doctors treat the disease more effectively.

At the same time, breakthroughs in drug therapies and radiation treatments continue to improve outcomes for patients with advanced stages of this cancer. These advancements not only enhance how well current treatments work but also offer new options that could reduce the chance of cancer coming back1. Investors may find promising opportunities in companies leading these innovations, as their success in research can translate directly into growth and profitability.

#Basal Cell Carcinoma: A Large, Underserved Market

Basal Cell Carcinoma (BCC) is the most common skin cancer2, seven times more prevalent than melanoma, yet it remains underserved and overlooked in public awareness. Primarily driven by sun exposure and fair skin, BCC grows slowly and usually stays localized. While less deadly than melanoma, untreated BCC can cause disfigurement and occasionally become invasive, highlighting the importance of timely medical intervention.

Medicus Pharma Ltd. (NASDAQ: MDCX) is one little-known micro-cap making strides with its innovative SkinJect microneedle patch for basal cell carcinoma (BCC). Currently in Phase 2 trials and already showing promising interim results, the SkinJect patch offers patients a painless, cost-effective alternative to invasive Mohs surgery. The treatment targets a lucrative $7B market and is on track to potentially secure FDA Fast-Track designation within months.

Notably, Medicus features among top industry players in the 360i market positioning matrix1 for companies active in the Basal Cell Carcinoma (BCC) treatment market. This includes the likes of Bausch Health Companies Inc (NYSE: BHC), Regeneron Pharmaceuticals Inc (NASDAQ: REGN), Roche Holding Ltd (OTC: RHHBY), Bristol-Myers Squibb Co (NYSE: BMY), Sanofi SA (NASDAQ: SNY), Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA), and Perrigo Company PLC (NYSE: PRGO).

Major pharmaceutical companies are constantly advancing skin cancer treatments, but under-the-radar players often drive breakthrough innovations—making them potential profit opportunities or attractive acquisition targets. Medicus Pharma is a micro-cap stock with a market cap below $50M. Given that it features here among pharmaceutical giants worth billions, its position on the list highlights its potential as an intriguing investment opportunity for investors on the lookout for biotech stocks with potential.

The FPNV Positioning Matrix helps businesses assess and categorize vendors in the Basal Cell Carcinoma Treatment Market. It measures vendor performance using two critical dimensions—Business Strategy and Product Satisfaction. Based on various factors, vendors receive scores, enabling businesses to compare their options clearly and select the most suitable partners for treating basal cell carcinoma. For instance, Medicus Pharma Ltd. achieved the highest Pathfinder score, positioning it to become a market leader within the next few years. 360i is an award-winning strategic, creative, and media agency recognized repeatedly by Ad Age’s A-List and named Adweek’s 2018 Breakthrough Media Agency of the Year.

RankCompanyMarket Cap

(subject to change)

Score
#1Bausch Health Companies Inc (NYSE: BHC)$2.5B8.26
#2Regeneron Pharmaceuticals Inc (NASDAQ: REGN)$82B8.06
#3Roche Holding Ltd (OTC: RHHBY)$248B7.12
#4Bristol-Myers Squibb Co (NYSE: BMY)$128B7.08
#5Sanofi SA (NASDAQ: SNY)$149B6.52
#6Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA)$46B6.38
#7Medicus Pharma Ltd (NASDAQ: MDCX)$43M6.07
#8Leo PharmaPrivate5.66
#9Perrigo Company PLC (NYSE: PRGO)$3.74B5.48
#10Amgen Inc (NASDAQ: AMGN)$176B4.93
#11AbbVie Inc (NYSE: ABBV)$377B4.83
#12Teva Pharmaceutical Industries Ltd (NYSE: TEVA)$18.3B4.82

Source: 360i Research Report1.

#A Stand-Out Alternative

Medicus Pharma distinguishes itself among these larger competitors due to its small market cap and substantial growth potential. The company is financially sound, covered by independent robust analyst projections from Maxim Group and Brookline Capital Markets, indicating over 240% and 300% upside from its $2.90 closing share price on 4 March 2025. (Note: Analyst targets are based on projections and assumptions that may not materialize and do not represent the view of the company.) The company has robust IP protection through 2035 and has received positive early feedback from both physicians and patients.

Medicus Pharma’s Phase 2 study, taking place across nine U.S. clinical sites1, is progressing well, with over half of the planned 60 participants already randomized. Encouraging interim analysis offers valuable early insights, reinforcing investor confidence ahead of the full data release. The SkinJect D-MNA patch uses dissolving microneedles to deliver chemotherapy directly into cancerous tissue, significantly minimizing systemic side effects. Interim data confirm a favorable safety profile at both the 100-microgram and 200-microgram doses, with no dose-limiting toxicities or serious adverse events reported. Additionally, no significant abnormalities appeared in laboratory tests, vital signs, ECGs, or physical examinations—further positive signals for investors.

Medicus Pharma plans to submit interim data to the FDA and request a Type C meeting in Q2 2025 to clarify clinical development and explore ways to expedite the program. A fast-track designation could significantly accelerate the path to FDA approval and market entry.

For investors and medical professionals looking to stay ahead in the healthcare sector, Medicus Pharma presents a compelling opportunity.

Explore This Stock Opportunity

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Healthcare

Important Notice And Disclaimer

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.